Allena Pharmaceuticals, Inc.
ALNA
|
$0.075
-12.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (431.58% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 9,156,242
http://www.allenapharma.com
Sec Filling | Patents | 83 employees
(United States) Allena Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company, which engages in the development, discovery, and commercialization of oral enzyme therapeutics to treat patients with kidney disorders. Its product pipeline includes reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria in adults; and ALLN-346, which is used for patients with hyperuricemia and moderate to severe chronic kidney disease. The company was founded by Robert Gallotto and Alexey L. Margolin on June 24, 2011 and is headquartered in Newton, MA.
kidney diseases kidney stones treatment kidney
add to watch list Paper trade email alert is off
Ayala Pharmaceuticals, Inc.
AYLA
|
$0.5036
5.84%
-0.7%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (15.3% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 7,463,718
http://www.ayalapharma.com
Sec Filling | Patents | 29 employees
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology. It is focused on the development and commercialization of small molecule therapeutics for patients suffering from rare and aggressive cancers. It also involved in in precision oncology, targeted therapy, drug development, companion diagnostics, and biomarkers. The company was founded in November 2017 and is headquartered in Rehovot, Israel.
cancer israel diagnostics
add to watch list Paper trade email alert is off
Harpoon Therapeutics, Inc.
HARP
|
$23.01
0.07%
6.6M
|
Health Technology
(0.0% 1d) (0.0% 1m) (3909.4% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees
(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
cancer immunotherapy glass t-cell treatment ceiling construction
add to watch list Paper trade email alert is off
Neovasc Inc.
NVCN
|
$30.03
1.66%
-2.02%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (615.5% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 81,306,886
http://www.neovasc.com
Sec Filling | Patents | 110 employees
(CA) Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. Its focuses on Neovast Tiara, and Neovasc Reducer products. The company was founded on November 2, 2000 and is headquartered in Richmond, Canada.
education cosira-ii heart
add to watch list Paper trade email alert is off
Pluristem Therapeutics, Inc.
PSTI
|
$1.0
-2.91%
8.0%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (192.0% volume)
Earnings Calendar: 2022-09-12
Market Cap: $ 32,347,584
http://www.pluristem.com
Sec Filling | Patents | 146 employees
(IL) Pluristem Therapeutics, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
israel t-cell clinical trials treatment ceiling
add to watch list Paper trade email alert is off
PLx Pharma Inc.
PLXP
|
$0.087
-4.6%
50M
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar: 2023-04-17
Market Cap: $ 2,534,979
http://www.plxpharma.com
Sec Filling | Patents | 12 employees
(US) PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.
gastrointestinal
add to watch list Paper trade email alert is off
Horizon Therapeutics Public Limited Company
HZNP
|
$116.3
0.03%
29M
|
Health Technology
(0.0% 1d) (0.0% 1m) (5.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (383.01% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 26,632,068,258
http://www.horizontherapeutics.com
Sec Filling | Patents | 1200 employees
Horizon Therapeutics Plc is a biopharmaceutical company, which is engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Rheumatology, and Inflammation segments. The Orphan and Rheumatology segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises of medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
add to watch list Paper trade email alert is off
HTG Molecular Diagnostics, Inc.
HTGM
|
$0.48
-20.0%
-26.08%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-79.4% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-46.41% volume)
Earnings Calendar: 2023-08-10
Market Cap: $ 1,062,832
http://www.htgmolecular.com
Sec Filling | Patents | 112 employees
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It offers instruments, reagents and services for molecular profiling applications. The firm serves biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
molecular diagnostics multiplexing diagnostics profitable
add to watch list Paper trade email alert is off
Infinity Pharmaceuticals, Inc.
INFI
|
$0.016
12.5%
1.1M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-89.5% 1y) (-4.8% 2d) (28.0% 3d) (0.0% 7d) (264.12% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 1,452,177
http://www.infi.com
Sec Filling | Patents | 25 employees
(US) Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
cancer msa
add to watch list Paper trade email alert is off
Novan, Inc.
NOVN
|
$0.0941
-24.84%
-32.91%
7.2M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-92.4% 1y) (0.0% 2d) (0.0% 3d) (-24.8% 7d) (318.21% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 2,636,246
http://www.novan.com
Sec Filling | Patents | 42 employees
(US) Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.
dermatological antiviral
add to watch list Paper trade email alert is off
Reata Pharmaceuticals, Inc.
RETA
|
$172.36
0.02%
0.03%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (76.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (165.53% volume)
Earnings Calendar: 2023-11-07
Market Cap: $ 5,789,158,047
http://www.reatapharma.com
Sec Filling | Patents | 220 employees
(US) Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.
education
add to watch list Paper trade email alert is off
Second Sight Medical Products, Inc.
EYES
|
$4.14
-0.24%
3.14%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap:
http://www.secondsight.com
Sec Filling | Patents | 112 employees
Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.
china prosthetics
add to watch list Paper trade email alert is off
Selecta Biosciences, Inc.
SELB
4
|
$0.8812
-8.0%
2.12%
0
|
Health Technology
(0.0% 1d) (0.0% 1m) (-23.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2023-11-02
Market Cap: $ 136,765,573
http://www.selectabio.com
Sec Filling | Patents | 39 employees
(US) Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
vaccine gene therapies msa treatment pompe disease
add to watch list Paper trade email alert is off
Zosano Pharma Corporation
ZSAN
|
$0.5576
7.23%
-5.85%
|
Health Technology
(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (-9.9% 3d) (0.0% 7d) (97.18% volume)
Earnings Calendar: 2022-08-10
Market Cap:
http://www.zosanopharma.com
Sec Filling | Patents | 56 employees
(US) Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system. The company was founded in October 2006 and is headquartered in Fremont, CA.
microneedle system qtrypta
add to watch list Paper trade email alert is off
ViewRay, Inc.
VRAY
|
$0.025
-39.9%
-61.87%
110M
|
Health Technology
(0.0% 1d) (0.0% 1m) (-97.7% 1y) (0.0% 2d) (0.0% 3d) (-39.9% 7d) (32.05% volume)
Earnings Calendar: 2023-08-01
Market Cap: $ 4,585,051
http://www.viewray.com
Sec Filling | Patents | 309 employees
(US) ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.
magnetic resonance radiation therapy treatment
add to watch list Paper trade email alert is off
Addex Therapeutics Ltd
ADXN
|
$18.74
-10.32%
12K
|
Health Technology
(0.0% 1d) (29.0% 1m) (3.7% 1y) (0.0% 2d) (-17.0% 3d) (-22.4% 7d) (145.04% volume)
Earnings Calendar:
Market Cap: $ 28,790,018
http://www.addextherapeutics.com
Sec Filling | Patents | 63 employees
(CH) Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.
neurological
add to watch list Paper trade email alert is off
Alterity Therapeutics Limited
ATHE
|
$2.33
9.39%
8.58%
170K
|
Health Technology
(0.0% 1d) (29.4% 1m) (-16.8% 1y) (0.0% 2d) (8.9% 3d) (13.1% 7d) (4197.87% volume)
Earnings Calendar:
Market Cap: $ 20,340,970
http://www.pranabio.com
Sec Filling | Patents | 12 employees
(AU) Alterity Therapeutics Ltd. engages in the development of therapeutic drugs designed to treat the underlying causes of degeneration of the brain as the aging process progresses. It focuses on Parkinson's movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
neurodegenerative alzheimer parkinson ath434 msa multiple system atroph α-synuclein alzheimer’s
add to watch list Paper trade email alert is off
ConforMIS, Inc.
CFMS
|
$2.26
0.44%
0
|
Health Technology
(0.0% 1d) (0.4% 1m) (57.6% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 17,803,134
http://www.conformis.com
Sec Filling | Patents | 271 employees
ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States; Germany; and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.
add to watch list Paper trade email alert is off
ARCA biopharma, Inc.
ABIO
|
$3.65
5.99%
98K
|
Health Technology
(0.0% 1d) (112.3% 1m) (81.5% 1y) (0.0% 2d) (-0.5% 3d) (6.8% 7d) (-53.85% volume)
Earnings Calendar:
Market Cap: $ 52,929,172
http://www.arcabiopharma.com
Sec Filling | Patents | 13 employees
(US) ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, Gencaro is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.
cardiovascular heart genetic treatment
add to watch list Paper trade email alert is off
Aethlon Medical, Inc.
AEMD
4
|
$1.5119
1.33%
620
|
Health Technology
(0.0% 1d) (-12.6% 1m) (287.6% 1y) (0.0% 2d) (1.3% 3d) (4.8% 7d) (-96.37% volume)
Earnings Calendar: 2024-02-13
Market Cap: $ 3,961,781
http://www.aethlonmedical.com
Sec Filling | Patents | 8 employees
(US) Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The firm operates through two segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in May 1998 and is headquartered in San Diego, CA.
cancer diagnostics hemopurifier blood filtration
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 0.48% 1.7M
|
Finance
|
22:30
NWFL | News | $24.6 2.03% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.685 39.71% 6.6K
|
Utilities
|
20:01
MNSB P 310 | $15.88 -2.93% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.54 0.28% 7.1K
|
Consumer Non-Durables
|
20:10